TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00176904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, Antithymocyte Globulin
Description: Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study: NCT02381821

Intervention type: OTHER
Intervention: 3 D ultrasound and Doppler examination
Description: Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis

Intervention type: OTHER
Intervention: 3 D ultrasound and Doppler examination
Description: Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis

Intervention type: DRUG
Intervention: GnRH agonist
Description: All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later

Intervention type: DRUG
Intervention: GnRH agonist
Description: All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
Study: NCT00006156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No injection of FSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: FSH
Description: FSH Stimulation Test
Study: NCT03463356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shame Intervention
Description: In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
Study: NCT03654456

Intervention type: BIOLOGICAL
Intervention: OSA
Description: The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
Study: NCT00721877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04017013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: 2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
Study: NCT02275364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test strip
Description: Class I device for the application to the nose to facilitate better air flow through the nose

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo strip
Description: Placebo strip

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray
Description: Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal spray
Description: Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
Study: NCT05541302

Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation
Study: NCT02681302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
Study: NCT02010632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel product Apolets®
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original clopidogrel product Plavix®
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
Study: NCT00070135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplantation
Study: NCT00652938

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccine (GSK580299) Cervarix TM
Description: IM administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine (GSK580299) Cervarix TM
Description: IM administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: IM administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: IM administration
Study: NCT01038115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Comparison of three different techniques for pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Comparison of three different techniques for pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Comparison of three different techniques for pulmonary vein isolation
Study: NCT04473690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose of KBP-COVID-19
Description: Low Dose of KBP-COVID-19 and adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose of KBP-COVID-19
Description: High Dose of KBP-COVID-19 and adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered saline solution
Study: NCT01653171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water (Placebo)
Description: Water 100 mL
Study: NCT03916744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery will take place on Day 15 (+/-2 days).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery will take place on Day 15 (+/-2 days).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery will take place on Day 15 (+/-2 days).
Study: NCT02676596

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 10 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 25 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 50 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 100 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 200 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: K-312 400 mg QD

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT02890537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core decompression/PREOB® implantation
Description: All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Core decompression/BMC implantation
Description: All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
Study: NCT00661661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg BID up to 10 mg BID until launch
Study: NCT04095039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
Study: NCT01065350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
Study: NCT04978155

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound performed by the surgeon after locoregional anesthesia
Description: Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
Study: NCT05199623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tailored Guizhi decoction
Description: Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory training (OT)
Description: Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory training (OT)
Description: Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
Study: NCT01975155

Intervention type: OTHER
Intervention: food questionnaire

Intervention type: OTHER
Intervention: food questionnaire

Intervention type: OTHER
Intervention: Urinary mycotoxin test

Intervention type: OTHER
Intervention: Urinary mycotoxin test
Study: NCT02385994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: enLighten Laser treatment with dual-pulse width and dual-wavelength
Study: NCT00084370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy
Study: NCT01618474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX
Description: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
Study: NCT02571374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: symbiotic group
Description: this group received sachets of symbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: this group received placebo
Study: NCT03687684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.
Study: NCT01473498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Haemodynamic management
Description: Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haemodynamic management
Description: Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg.
Study: NCT04363099

Intervention type: OTHER
Intervention: observational
Description: observational management of outpatients COVID 19
Study: NCT03687684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.
Study: NCT02239133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVATE vaginal pessary
Study: NCT01338402

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel contact lens
Study: NCT01653171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
Study: NCT00736489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Dry powder for inhalation, single dose
Study: NCT01653171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 500 mg
Description: 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 1000 mg
Description: 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
Study: NCT02894385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
Study: NCT00736489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Dry powder for inhalation, single dose
Study: NCT02894385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
Study: NCT01024829

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT01338402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color
Study: NCT00736489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for inhalation, single dose
Study: NCT02174887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Gemcitabine
Description: Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days: